Breaking News
June 22, 2018 - AAA doses first patients in two clinical studies with PSMA-R2 for prostate cancer
June 22, 2018 - Pelvic pain a major issue for women nearing mid-life, research reveals
June 22, 2018 - Researchers develop reliable DNA barcodes for biomedical research
June 22, 2018 - New risk-prediction model may help identify diabetic patients at high risk of pancreatic cancer
June 22, 2018 - Study reveals how mTORC1-driven changes in crowding could influence major diseases
June 22, 2018 - Researchers uncover new therapeutic opportunity in the treatment of malignant melanoma
June 22, 2018 - UC Riverside researcher receives grants to advance cancer, ALS research
June 22, 2018 - Radiation therapy alone may be enough to treat older, sicker patients with anal cancers
June 22, 2018 - Technical report describes how to make accurate particle size measurements on carbon black samples
June 22, 2018 - Nocdurna (desmopressin acetate) Approved by FDA as First Sublingual Tablet to Treat Nocturia due to Nocturnal Polyuria
June 22, 2018 - Neuroscientists locate neurons in the brain that respond when a visual target is found
June 22, 2018 - First human Keystone virus infection reported
June 22, 2018 - New study reveals how ‘good’ bacteria help in regulating our metabolism
June 22, 2018 - Osteopathic manual therapy affecting the diaphragm improves chronic low back pain
June 22, 2018 - Researchers create revolutionary model to study pulmonary diseases
June 22, 2018 - Diagnosing Heart Disease Using AI
June 22, 2018 - Increasing biodefense risks posed by synthetic biology
June 22, 2018 - Many Women Report Vasomotor Symptoms in Their 60s
June 22, 2018 - Rare mutation of gene carried by Quebec family gives insight into how the brain is wired
June 22, 2018 - Chemists find new way to make enzymes do a non-natural reaction
June 22, 2018 - Summer is good time to check for signs of skin cancer
June 22, 2018 - Innovative method can help identify patients with spastic cerebral palsy
June 22, 2018 - Exercise alters characteristics of blood to reduce inflammation in obese people
June 22, 2018 - Researchers examine complications across different types of breast reconstructive surgeries
June 22, 2018 - Rhesus macaque model could be useful to test therapies for congenital Zika virus syndrome
June 22, 2018 - AHA: New Insights Into Sickle Cell and Stroke Risk
June 22, 2018 - Doctors prescribe opioids at high rates to those at increased overdose risk
June 22, 2018 - Reduction in US cigarette smoking rates
June 22, 2018 - Preconception binge drinking may have negative effect on future offspring
June 22, 2018 - FDA expands approval of novel diabetes management device to include younger pediatric patients
June 22, 2018 - Researchers confirm weight loss benefits of the 16:8 diet
June 22, 2018 - FDA approves Eversense CGM system for use in adults with diabetes
June 22, 2018 - State opioid monitoring programs are not created equal
June 22, 2018 - Autistic teens who are bullied have higher rates of depression
June 22, 2018 - Penn Medicine team launches universal stroke awareness program
June 22, 2018 - Scientists discover the molecular trigger of necroptosis
June 22, 2018 - Researchers report unusually high levels of herpesvirus in the brains of people with Alzheimer’s disease
June 22, 2018 - Theoretical models predict how juveniles evolve to be more susceptible than adults to infection
June 22, 2018 - USC study reveals how the cell launches emergency response to repair damaged DNA
June 22, 2018 - $1.9 million grant aims to enhance behavioral health services in community-based settings
June 22, 2018 - New 3D imaging technique could improve arthritis treatment
June 22, 2018 - Cytokinetics Announces Data From Phase 2 Clinical Study of Reldesemtiv in Patients With Spinal Muscular Atrophy
June 22, 2018 - Polarized cells give the heart its fully developed form
June 21, 2018 - Stem cells appear to help fight obesity in animal models
June 21, 2018 - Harnessing Pediatric Cancer Genomic Data in the Cloud
June 21, 2018 - Training nursing students with cost-effective 3D-printed task trainers
June 21, 2018 - Study provides insight into how planned and spontaneous movements are processed in the brain
June 21, 2018 - Suicide Prevention | SAMHSA – Substance Abuse and Mental Health Services Administration
June 21, 2018 - From designer microbes to stem cells, researchers are investigating new strategies to treat bowel disease
June 21, 2018 - Study suggests state-of-the-art genomic testing for routine autopsy of stillbirths
June 21, 2018 - Christiana Care Health System opens first Epilepsy Monitoring Unit in Delaware
June 21, 2018 - CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
June 21, 2018 - Youths Treated for Non-Suicidal Self Harm at Increased Risk of Suicide Within a Year
June 21, 2018 - WVU researchers increase colorectal cancer screening rates in West Virginia
June 21, 2018 - Pediatric kidney recipients often have subclinical inflammation
June 21, 2018 - OHSU Knight Cancer Institute Director wins 2018 Tang Prize in Biopharmaceutical Science
June 21, 2018 - Researchers study broader effects of neonics on wildlife
June 21, 2018 - Study provides new insight on how antibiotics affect the gut microbiome
June 21, 2018 - InHealth Technologies becomes exclusive distributor of RENÚ Voice, RENÚ Gel in the United States
June 21, 2018 - New analysis links higher BMI to lower breast cancer risk for younger women
June 21, 2018 - Interactive preclinical PET-MR workshop demonstrates benefits of multi-modality imaging
June 21, 2018 - Gene signature could improve early diagnosis of TB
June 21, 2018 - Psychiatric Drug Lithium Tied to Birth Defect Risk
June 21, 2018 - Preclinical study suggests ARID1a may be useful biomarker for immunotherapy
June 21, 2018 - Risks of cancer and mortality found to be lowest in light drinkers
June 21, 2018 - Fetal immune cells are fast-acting first responders to microbes in adulthood
June 21, 2018 - Researchers invent medical device for proliferation, differentiation of neural stem cells
June 21, 2018 - Study explores current understanding of human physiology, pathology, trauma and surgery in space
June 21, 2018 - Scientists explore interactions between chromosomes 12 and 17
June 21, 2018 - People with severe obesity constantly try to reduce or control their weight
June 21, 2018 - Relaxing ‘brain tingles’ may have benefits for both mental and physical health
June 21, 2018 - Breakthrough discovery reveals brain metals that may drive progression of Alzheimer’s disease
June 21, 2018 - New methods of fragment-based lead discovery to identify potential antibiotics
June 21, 2018 - Recovery and Treatment | NIH MedlinePlus the Magazine
June 21, 2018 - Study finds cell-free DNA profiling as versatile method to monitor UTIs
June 21, 2018 - ‘Hidden’ driver discovered that helps prime the anti-tumor immune response
June 21, 2018 - Groundbreaking discovery could be key to preventing cancer metastasis
June 21, 2018 - Impulse control disorders found to be more common in people taking Parkinson’s drugs
June 21, 2018 - Study finds possible link between Type 2 diabetes and common white pigment
June 21, 2018 - Most emergency department patients wish to be involved in medical decision-making
FGF-18 Drug Builds Knee Cartilage in Osteoarthritis

FGF-18 Drug Builds Knee Cartilage in Osteoarthritis

image_pdfDownload PDFimage_print

Action Points

  • Note that this study was published as an abstract and presented at a conference. These data and conclusions should be considered to be preliminary until published in a peer-reviewed journal.

SAN DIEGO — Intra-articular injections of a protein drug derived from fibroblast growth factor-18 in patients with knee osteoarthritis (OA) led to increases in mean cartilage thickness within the joint after two years, although no significant change in symptom scores was seen, a researcher said here.

At the highest dose of the drug, called sprifermin, mean total MRI-measured cartilage thickness in the knee joint increased by 0.03 mm at the year 2 evaluation, whereas patients receiving placebo injections had a loss of 0.02 mm in cartilage thickness, said Marc Hochberg, MD, of the University of Maryland School of Medicine in Baltimore.

Other radiologic measures of joint structure also showed a significant benefit for sprifermin at the higher dose, Hochberg said at a late-breaking session at the American College of Rheumatology annual meeting. But the same downward trajectory was seen in scores on the Western Ontario and McMaster Universities Osteoarthritis (WOMAC) scale for all treatment groups including placebo.

Hochberg noted that the phase II study is planned to extend for 5 years, and said the investigators still hold out hope that clinical symptoms will improve with sprifermin in these later years. He also pointed out that patients were permitted to take pain medications during the study, which could have masked clinical effects from the drug during this initial portion of the study.

In the trial, approximately 550 patients were randomized to receive placebo or one of four doses of sprifermin, in injections given three times over a week, repeated every 6 months through month 18. Sprifermin dosing groups were 30 mcg per cycle every 12 months; 30 mcg per cycle every 6 months; 100 mcg per cycle every 12 months; or 100 mcg per cycle every 6 months. To maintain blinding, the 12-month sprifermin groups received placebo injections at months 6 and 18.

Median patient age was about 65, and 70% were female. OA was graded at Kellgren-Lawrence level 2 in roughly 70%; the rest were at grade 3. Mean WOMAC score at baseline was about 40.

At the end of year 2, WOMAC scores declined by 18 to 22 points in all groups, with no significant differences or any trends worth noting.

However, the trial technically succeeded because its prespecified primary endpoint was change in total knee joint cartilage thickness, and all secondary endpoints except for WOMAC score were also radiologic assessments of cartilage thickness and joint space width.

On those measures, the two higher sprifermin doses did very well (Results with the 30-mcg doses, whether patients received two or four cycles, did not differ markedly from placebo).

Highly significant differences from the placebo group were seen in the two 100-mcg dosing groups for MRI-measured medial and lateral tibiofemoral cartilage thickness, both overall and in the central subregions of these cartilage compartments. Medial and lateral minimum joint space width, as measured by x-ray, also significantly favored the high-dose sprifermin groups.

The high-dose groups did experience higher rates of acute inflammatory responses: 22% and 23% for those receiving four and two cycles of 100 mcg, respectively, compared with 13.5% for placebo. All of these occurred in the first cycle, Hochberg said, and none led to study dropout. In all other respects, rates of adverse events of various kinds were the same in all groups, he reported.

Sprifermin’s developer, Merck KGaA of Darmstadt, Germany, said it was “highly encouraged” by the study results, but stopped short of promising a phase III trial.

The study was sponsored by Merck KGaA. Co-authors included employees of EMD Serono, a unit of Merck KGaA.

Hochberg disclosed relevant relationships with Bioiberica, Bristol Myers-Squibb, EMD Serono, Galapagos, IBSA, Eli Lilly, Novartis, Pfizer, Plexxikon, Samumed, Theralogix, and TissueGene.

2017-11-09T09:30:00-0500

Tagged with:

About author

Related Articles